Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q6ZN66
UPID:
GBP6_HUMAN
Alternative names:
GTP-binding protein 6; Guanine nucleotide-binding protein 6
Alternative UPACC:
Q6ZN66; A2RRM3; Q6ZN86; Q7Z3F0
Background:
Guanylate-binding protein 6, also known as GTP-binding protein 6 or Guanine nucleotide-binding protein 6, plays a pivotal role in the innate immune response. It is an Interferon (IFN)-inducible GTPase that combats a wide array of pathogens including bacterial pathogens like Listeria monocytogenes and Mycobacterium bovis BCG, as well as the protozoan pathogen Toxoplasma gondii. Its ability to confer protection against these pathogens underscores its importance in the immune system.
Therapeutic significance:
Understanding the role of Guanylate-binding protein 6 could open doors to potential therapeutic strategies.